John K Yan

US Patent:

6471980, Oct 29, 2002

Filed:

Feb 13, 2001

Appl. No.:

09/782927

Inventors:

Motasim Sirhan - Sunnyvale CA
John Yan - Los Gatos CA

Assignee:

Avantec Vascular Corporation - Sunnyvale CA

International Classification:

A61F 202

US Classification:

424423, 424424, 424425, 424426

Abstract:

The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled mycophenolic acid delivery with increased efficacy to selected locations within a patients vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing mycophenolic acid at a rate selected to inhibit smooth muscle cell proliferation.

US Patent:

6569180, May 27, 2003

Filed:

Jun 2, 2000

Appl. No.:

09/585943

Inventors:

Motasim Sirhan - Sunnyvale CA
John Yan - Los Gatos CA
Kevin Gertner - Los Gatos CA

Assignee:

Avantec Vascular Corporation - Sunnyvale CA

International Classification:

A61M 2510

US Classification:

606194, 606195, 623 111, 604103

Abstract:

An intravascular balloon catheter comprises a tubular catheter body having a balloon structure removably mounted over the catheter body. The catheter body has a guidewire lumen , and the catheter body may be left in place within a patients vasculature while the balloon structure is withdrawn and optionally a second balloon structure introduced over the catheter body. The catheter and methods of the present invention are particularly suitable for performing angioplasty and subsequent procedures, such as stent placement, which are best performed using successive interventional balloon structures.

US Patent:

6602282, Aug 5, 2003

Filed:

May 4, 2000

Appl. No.:

09/565560

Inventors:

John Yan - Los Gatos CA

Assignee:

Avantec Vascular Corporation - San Jose CA

International Classification:

A61F 206

US Classification:

623 115

Abstract:

Luminal prostheses comprise adjacent expansible segments, typically serpentine ring segments joined by sigmoidal links. By properly orienting the sigmoidal links and aligning hinge regions on adjacent serpentine rings, enhanced opening characteristics can be obtained. Additionally, by varying the mechanical characteristics of adjacent serpentine rings, program expansion of the luminal prostheses over their lengths may be obtained. The disclosed prostheses also have controllable opening characteristics and can be crimped to small diameters.

US Patent:

6605114, Aug 12, 2003

Filed:

Oct 29, 1999

Appl. No.:

09/430230

Inventors:

John Y. Yan - Los Gatos CA
Randy Chan - San Jose CA

Assignee:

Advanced Cardiovascular Systems, Inc. - Santa Clara CA

International Classification:

A61F 206

US Classification:

623 143, 623921, 623 146, 427 225

Abstract:

A method for delivering heparin, wherein an implantable stent is coated with a material that attracts heparin and with which heparin forms a bond. The stent is exposed to a heparin containing solution just prior to implantation or is first implanted and then exposed to heparinized blood. As heparin becomes detached from the stent, the implantation site is exposed to heparin to restore an effective level and thereby prevent thrombosis.

US Patent:

6648911, Nov 18, 2003

Filed:

Nov 20, 2000

Appl. No.:

09/717910

Inventors:

Motasim Sirhan - Sunnyvale CA
John Yan - Los Gatos CA
Kevin Gertner - Los Gatos CA

Assignee:

Avantec Vascular Corporation - Sunnyvale CA

International Classification:

A61F 206

US Classification:

623 115

Abstract:

The present invention is directed to method and apparatus for treating vulnerable tissue sites, such as aneurysms in the abdominal area or in the thoracic cavity, and expanded tissues on various organs and body surfaces such as the heart. The apparatus of the present invention, are containment members for at least partially containing the vulnerable tissue site, thus preventing or minimizing the further vulnerability or growth of the site. Additionally, or alternatively, the containment members can apply resistive force to the vulnerable tissue site. The force can be compressive against the exterior surface of the tissue site. The containment members of the present invention can be used alone or in combination with support members, such as stent/grafts, in treating a tissue site. In this embodiment, the support member is disposed within the inner lumen of the vulnerable tissue site with the containment member disposed on the exterior surface of the lumen.

US Patent:

6723120, Apr 20, 2004

Filed:

Sep 3, 2002

Appl. No.:

10/235033

Inventors:

John Y. Yan - Los Gatos CA

Assignee:

Advanced Cardiovascular Systems, Inc. - Santa Clara CA

International Classification:

A61F 206

US Classification:

623 115, 623 14

Abstract:

A porous prosthesis for delivering a medication to the site of implantation is disclosed.

US Patent:

6776792, Aug 17, 2004

Filed:

Apr 24, 1997

Appl. No.:

08/847763

Inventors:

John Y. Yan - Los Gatos CA
Randy Chan - San Jose CA

Assignee:

Advanced Cardiovascular Systems Inc. - Santa Clara CA

International Classification:

A61F 206

US Classification:

623 115, 623 143, 623 146, 427 225

Abstract:

An implantable stent is coated with a material that attracts heparin and with which heparin forms a bond. The stent is exposed to a heparin containing solution just prior to implantation or is first implanted and then exposed to heparinized blood. As heparin becomes detached from the stent, the implantation site is exposed to heparin to restore an effective level and thereby prevent thrombosis.

US Patent:

6858221, Feb 22, 2005

Filed:

Sep 11, 2002

Appl. No.:

10/242334

Inventors:

Motasim Sirhan - Sunnyvale CA, US
John Yan - Los Gatos CA, US

Assignee:

Avantec Vascular Corporation - Sunnyvale CA

International Classification:

A61F002/02
A61F002/06

US Classification:

424423, 424424, 424425, 424426, 623 11, 623 142

Abstract:

The present invention provides improved devices and methods for minimizing and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the present invention provides luminal prostheses which allow for programmed and controlled mycophenolic acid delivery with increased efficacy to selected locations within a patient's vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an expansible structure and means on or within the structure for releasing mycophenolic acid at a rate selected to inhibit smooth muscle cell proliferation.